Pages that link to "Q48470407"
Jump to navigation
Jump to search
The following pages link to Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). (Q48470407):
Displaying 10 items.
- DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma (Q30315797) (← links)
- Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer (Q34852774) (← links)
- Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer (Q35858069) (← links)
- Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer (Q36439420) (← links)
- Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group (Q36459767) (← links)
- A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer (Q36863055) (← links)
- Docetaxel in the treatment of advanced non-small-cell lung cancer. (Q37242661) (← links)
- A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress (Q38713515) (← links)
- A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC). (Q43849368) (← links)
- Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial. (Q45923820) (← links)